CM
SUPN icon

Castleark Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Castleark Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-110,880
Closed -$4.02M – 310
2023
Q1 		$4.02M Buy
110,880
+52,440
+90% +$2.02M 0.2% 118
2022
Q4 		$2.08M Buy
58,440
+1,050
+2% +$36.5K 0.11% 162
2022
Q3 		$1.94M Sell
57,390
-14,600
-20% -$475K 0.11% 152
2022
Q2 		$2.08M Buy
71,990
+30,010
+71% +$860K 0.11% 154
2022
Q1 		$1.36M Buy
+41,980
New +$1.29M 0.06% 203
2019
Q1 		– Sell
-4,280
Closed -$142K – 403
2018
Q4 		$142K Hold
4,280
– – 0.01% 345
2018
Q3 		$215K Sell
4,280
-297,565
-99% -$14.7M 0.01% 349
2018
Q2 		$18.1M Buy
+301,845
New +$15.6M 0.56% 44
2017
Q4 		– Sell
-316,940
Closed -$12.7M – 440
2017
Q3 		$12.7M Buy
316,940
+93,590
+42% +$4.05M 0.4% 81
2017
Q2 		$9.63M Sell
223,350
-57,741
-21% -$2.06M 0.31% 106
2017
Q1 		$8.8M Sell
281,091
-49,450
-15% -$1.33M 0.28% 117
2016
Q4 		$8.35M Sell
330,541
-27,835
-8% -$622K 0.27% 130
2016
Q3 		$8.86M Sell
358,376
-85,785
-19% -$1.94M 0.27% 117
2016
Q2 		$9.05M Buy
444,161
+218,399
+97% +$3.87M 0.29% 97
2016
Q1 		$3.44M Sell
225,762
-33,510
-13% -$437K 0.11% 209
2015
Q4 		$3.48M Sell
259,272
-115,115
-31% -$1.78M 0.1% 214
2015
Q3 		$5.25M Sell
374,387
-66,138
-15% -$1.23M 0.17% 153
2015
Q2 		$7.48M Buy
+440,525
New +$6.27M 0.2% 139

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Castleark Management's SUPN Position: Q2 2023 in Review

Castleark Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 110,880 shares — an estimated $4.02M sold.

Castleark Management first reported a position in SUPN in Q2 2015 and held it in 18 quarters. The position peaked at $18.1M in Q2 2018. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • Castleark Management reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Castleark Management sold 110,880 Supernus Pharmaceuticals shares in Q2 2023, an estimated $4.02M.
  • Castleark Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 18 quarters.
  • Castleark Management's Supernus Pharmaceuticals position peaked at $18.1M in Q2 2018.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Castleark Management's 13F filing for Q2 2023, filed 16 Aug 2023.